FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Navamedic has completed its previously announced acquisition of dne pharma's business for up to Nkr225m ($22m).

As supply chain disruption persists in pharma, global logistics providers with the expertise to overcome any challenge are essential.

Acumen has entered a partnership, option and licence agreement with JCR for developing an oligomer-targeted EBD for Alzheimer’s disease.

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.

In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

Ultragenyx Pharmaceutical has received a complete response letter (CRL) from the FDA concerning its BLA for UX111 (ABO-102).